SCGB2A2
Mammaglobin-A
Also known as: MGB1, MGC71974, PSBP1, SG2A2_HUMAN, UGB2
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13296
- Gene
- SCGB2A2
- Ensembl
- ENSG00000110484
- Chromosome
- 11
- Canonical length
- 93 aa
- Protein class
- Cancer-related genes, Predicted secreted proteins
- Secretome location
- Secreted in female reproductive system
OverviewNCBI Gene
Predicted to be involved in androgen receptor signaling pathway. Predicted to be located in extracellular region. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
93 residues, UniProt reviewed canonical sequence.
>Q13296|SCGB2A2
1 MKLLMVLMLA ALSQHCYAGS GCPLLENVIS KTINPQVSKT EYKELLQEFI DDNATTNAID
61 ELKECFLNQT DETLSNVEVF MQLIYDSSLC DLFLocalizationUniProt · AlphaFold · HPA
Whether an antibody against SCGB2A2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 2,629 nTPM
Expression across tissuesHPA
Tissue
- breast: 2,629 nTPM
- skin: 689 nTPM
- cervix: 289 nTPM
- salivary gland: 173 nTPM
- esophagus: 72 nTPM
- adipose tissue: 32 nTPM
Single-cell type
- breast secretory cells: 3,945 nCPM
- breast hormone-responsive cells: 1,298 nCPM
- submucosal glandular cells: 357 nCPM
- endometrial glandular cells: 254 nCPM
- endometrial luminal cells: 41 nCPM
- endometrial ciliated cells: 33 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- midbrain: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about SCGB2A2.
Disease | ImmuneIEDB
Conditions an epitope on SCGB2A2 was assayed in.
- breast cancer T cell
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.91
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.23
- DepMap mean gene effect
- 0
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads SCGB2A2 as an antibody target. Whether an autoantibody or antibody against SCGB2A2 could matter depends on whether native SCGB2A2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
SCGB2A2 is annotated as secreted, so native SCGB2A2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label SCGB2A2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...